Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

Trey Thoelcke

Thu, August 20, 2026 at 5:40 PM GMT+3 3 min read

Quick Read

SPTX's Glyph prodrug platform has generated 24 candidates, with lead asset GlyphAllo entering Phase 2b for MDD and topline results expected in 1H 2027.
BMY previously paid $14 billion for Karuna Therapeutics, co-founded by Seaport CEO Daphne Zohar, making it the top-ranked potential acquirer.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and SPTX didn't make the cut. Grab the names FREE today.

Seaport Therapeutics (NASDAQ:SPTX) opened at $25.44 on August 20, 2026, carrying a market capitalization of roughly $1.4 billion. The stock has traded between a post-IPO high of $26.32 and a low below its $19.84 May 1 open, gaining 20.2% over the past month. The company completed an upsized $260 million gross-proceeds IPO in May 2026. It holds $427.26 million in cash and investments, reported a Q2 2026 net loss of $62.60 million, and guides to a runway into 2029. Seaport is a clinical-stage and pre-commercial company with no product revenue.

24/7 Wall St.

Why a Strategic Buyer Would Want It

Seaport's Glyph platform has generated over 24 small-molecule prodrugs designed to overcome first-pass metabolism and bioavailability limits. Lead asset GlyphAllo is a Glyphed oral prodrug of allopregnanolone in the Phase 2b BUOY-1 trial in MDD (approximately 360 patients), with topline data expected 1H 2027. GlyphAgo, a Glyphed agomelatine prodrug for generalized anxiety disorder, delivered a 6.8-fold bioavailability increase and 10-fold lower PK variability in Phase 1. CEO Daphne Zohar said the results "significantly de-risks future clinical development of this program."

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and SPTX didn't make the cut. Grab the names FREE today.

What an Acquirer Would Actually Be Buying

Per the S-1, Glyph's prodrug modifications create new composition-of-matter intellectual property, and Seaport holds exclusive global rights to develop and commercialize its product candidates. The company was carved out of PureTech in April 2024 pursuant to the Asset Transfer Agreement, issuing PureTech 40,000,000 Series A-1 preferred shares and 302,161 common shares, plus contingent milestones and royalties between 3% and 5% on net sales of each Seaport Glyph Product. GlyphCele carries a separate Monash University license with 3% to 5% royalties and milestones up to $1.075 million per licensed product.

Ranking the Plausible Acquirers

Bristol Myers Squibb (NYSE:BMY) has a market cap of $136.6 billion. BMS acquired Karuna Therapeutics, co-founded by Zohar and Steven Paul, in March 2024 for $14 billion. The Cobenfy playbook maps directly onto Seaport's asset base.
Johnson & Johnson (NYSE:JNJ), with a $653.5 billion market cap, has closed its $14.6 billion Intra-Cellular acquisition. Sharon Mates, Intra-Cellular's former CEO, has joined the Seaport board, strengthening that connection.
AbbVie (NYSE:ABBV) has a $457.5 billion market cap. It owns a deep neuroscience franchise and faces Humira erosion.
Sanofi (NASDAQ:SNY), at $106.4 billion, has publicly telegraphed CNS specialty-care ambitions.

What About Private Equity or Alternative Capital?

With no revenue to leverage and binary Phase 2b risk, sponsor-led buyouts are impractical. A royalty or structured-equity partner is more realistic, though the balance sheet already funds operations into 2029.

What to Watch

Analyst coverage skews positive, and the $38 consensus target price signals room to run. The decisive catalyst is BUOY-1 topline in 1H 2027. That is preceded by the GlyphAllo driving-simulation readout in 2H 2026 and the initiation of the GlyphAgo Phase 2a. Investors should also watch 13D/13G filings and unusual options flow around those data points.